Non-viral gene therapies emerge as key players amid viral safety bottlenecks

Non-viral gene therapies may hold potential to overcome some safety, pricing and manufacturing hurdles linked to viral alternatives. Non-viral gene therapies may ease some safety, pricing and manufacturing challenges linked to viral vectors, but experts say both approaches will still have a place. Non-viral gene therapies could hold the potential to overcome some of the safety and manufacturing hurdles associated with viral methods, experts tell Pharmaceutical Technology. Credit: MicroOne / Shutterstock.com. Cell and gene therapies (CGTs) have long been heralded for their potential to transform outcomes of patients with complex, hard-to-treat diseases, with several of these medicines offering previously unattainable…

Source: Pharmaceutical Technology